These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24803795)

  • 1. Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?
    Rizzo G; Pugliese D; Armuzzi A; Coco C
    World J Gastroenterol; 2014 May; 20(17):4839-45. PubMed ID: 24803795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
    Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
    World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
    Punekar YS; Hawkins N
    Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulcerative Colitis Treatment Patterns and Cost of Care.
    Null KD; Xu Y; Pasquale MK; Su C; Marren A; Harnett J; Mardekian J; Manuchehri A; Healey P
    Value Health; 2017 Jun; 20(6):752-761. PubMed ID: 28577692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.
    Tappenden P; Ren S; Archer R; Harvey R; James MM; Basarir H; Stevens J; Lobo A; Hoque S
    Pharmacoeconomics; 2016 Oct; 34(10):1023-38. PubMed ID: 27125898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice.
    Nattiv R; Wojcicki JM; Garnett EA; Gupta N; Heyman MB
    World J Gastroenterol; 2012 Mar; 18(11):1229-34. PubMed ID: 22468086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
    Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
    J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
    Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
    United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry-based cohort study.
    Nambu R; Kudo T; Tachibana N; Shimizu H; Mizuochi T; Kato S; Inoue M; Kumagai H; Ishige T; Kunisaki R; Noguchi A; Yodoshi T; Hagiwara SI; Nishimata S; Kakuta F; Saito T; Iwama I; Hirano Y; Shimizu T; Arai K;
    J Gastroenterol Hepatol; 2024 Feb; 39(2):312-318. PubMed ID: 38058020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
    Tsai HH; Punekar YS; Morris J; Fortun P
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.
    Narula N; Marshall JK; Colombel JF; Leontiadis GI; Williams JG; Muqtadir Z; Reinisch W
    Am J Gastroenterol; 2016 Apr; 111(4):477-91. PubMed ID: 26856754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.